1717 Life Science Ventures

1717 Life Science Ventures is a German private life sciences company focused on precision radiopharmaceuticals for the diagnosis and treatment of malignant diseases. Publicly available descriptions indicate the company develops and validates radiopharmaceutical assets and has also operated as an investor in healthcare and radiopharmaceutical opportunities. The company is closely associated with the development of CXCR4-targeted theranostics through PentixaPharm, a joint venture with Scintomics. Available information suggests its core emphasis is oncology, especially targeted diagnostic and therapeutic nuclear medicine products. Overall, 1717 Life Science Ventures appears to function as both a radiopharma asset developer and an investment vehicle within the life sciences sector.